These findings align with the observation that TP53 mutations are relatively rare in de novo AML (5 %–10 % of cases) but enriched in therapy‐related AML (∼30 %), implying that TP53 inactivation is not a prerequisite for AML initiation in most contexts [35]. The gene discussed is TP53; the disease is acute myeloid leukemia.